Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127633 · ClinicalTrials.gov registry record · Phase 3
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,457
- Enrollment target
NCT01127633: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT01127633 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,457 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01127633, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,457 participants
- Enrollment target
Study Summary
This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).
Primary Outcome
The number of participants with 1 or more AEs assessed as related to the study drug and is summarized cumulatively. In addition, the number of participants with 1 or more serious AEs is summarized cumulatively. A serious AE is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any othe
Interventions
- DRUG Placebo
- DRUG Solanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,457 participants |
| Start Date | 2010-12 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
Why NCT01127633 stopped before completion
NCT01127633 is an interventional study that assigns participants to a tested intervention. Its 1,457 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01127633 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01127633 about?
NCT01127633 is a clinical study titled "Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease". This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).
What is the current status of trial NCT01127633?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,457 participants. The study started on 2010-12. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01127633?
The interventions under investigation include: Placebo (DRUG), Solanezumab (DRUG).
Who is sponsoring clinical trial NCT01127633?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01127633's enrollment target sits among peer trials
1,457 164th of 2000 higher than 1,837 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia